Back to Authors

Grossman, Stuart A.

https://orcid.org/0000-0002-3726-7679

A5010420312 | I130238516

Mayo Clinic

University of Minnesota

Citations 14

Genetic landscape of extreme responders with anaplastic oligodendroglioma: NRG Oncology/RTOG 9402.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2054-2054

10.1200/jco.2016.34.15_suppl.2054

Validating RNAseq-signatures of vorinostat (VOR) sensitivity and resistance in patients with newly diagnosed glioblastoma (GBM) treated with VOR, temozolomide and radiation therapy in Alliance N0874/ABTC-0902.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2029-2029

10.1200/jco.2016.34.15_suppl.2029

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

Neuro-Oncology | August 21, 2017 | Volume: 20 | Issue: 4 | Pages: 546-556

10.1093/neuonc/nox161 | PMID 29016887

It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology

Journal of Clinical Oncology | July 18, 2011 | Volume: 29 | Issue: 24 | Pages: 3211-3213

10.1200/jco.2011.36.6328 | PMID 21768451